U.S. markets open in 6 hours 15 minutes

Medtronic plc (MDT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
118.31+1.50 (+1.28%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close116.81
Bid0.00 x 800
Ask0.00 x 800
Day's Range117.23 - 119.00
52 Week Range72.13 - 122.15
Avg. Volume4,451,654
Market Cap159.248B
Beta (5Y Monthly)0.71
PE Ratio (TTM)43.18
EPS (TTM)2.74
Earnings DateFeb 23, 2021
Forward Dividend & Yield2.32 (1.99%)
Ex-Dividend DateDec 21, 2020
1y Target Est129.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-18% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Barrons.com

    Brain, Spine Stimulation Devices Are a Post-Pandemic Winner, Says Raymond James

    The equipment, made by companies such as Medtronic and Abbott Laboratories, offers an alternative to drugs for pain relief.

  • Intel Chairman Planning Up to $1 Billion Health-Tech SPAC IPO

    Intel Chairman Planning Up to $1 Billion Health-Tech SPAC IPO

    (Bloomberg) -- Intel Corp. Chairman Omar Ishrak is planning to raise funds for a blank-check firm targeting deals in the health technology sector, according to people with knowledge of the matter.Ishrak, who previously ran medical device giant Medtronic Plc, could file public registration documents with the U.S. Securities and Exchange Commission as soon as Tuesday, the people said, asking not to be identified because the information is private. Ishrak is targeting to raise about $750 million to $1 billion for the special purpose acquisition company, or SPAC, they said.Goldman Sachs Group Inc. is leading preparations for the initial public offering, the people said. Hedge fund manager Joshua Fink, who is the son of BlackRock Inc.’s Larry Fink, and Medtronic executive Jean Nehme will have senior roles at the blank-check company, the people said. Ishrak is poised to be chairman, they said.A representative for Intel couldn’t immediately comment on behalf of Ishrak. A spokesperson for Goldman Sachs declined to comment.SPACs, once an obscure vehicle used by a few companies to go public, catapulted to record levels in 2020, raising about $79 billion on U.S. exchanges, according to data compiled by Bloomberg.That momentum has carried into 2021, with 53 blank-check companies raising $15 billion in listings so far in January, the data show. Forty-seven more SPACs this month have announced plans to raise a combined $11.7 billion and are awaiting IPOs.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Medtronic Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Trial in Parkinson's Disease Patients
    CNW Group

    Medtronic Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Trial in Parkinson's Disease Patients

    ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease PatientsDUBLIN, Jan. 14, 2021 /CNW/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease (PD).